Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1490 - Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET)


08 Oct 2016


Poster Display


Lyudmila Bazhenova


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


L. Bazhenova1, R. Mehra2, T. Nagy3, L. Cavanna4, J. Lee5, J. Han6, H.K. Kim7, B. Halmos8, M. Shum9, M. Schreeder10, I. Rybkin11, F. Badin12, R. Mena13, P.A. Jänne14, J. Christensen15, V. Tassell16, R. Chao16, D. Faltaos17, D. Kim18

Author affiliations

  • 1 Moores Cancer Center, University of California San Diego, 92093 - La Jolla/US
  • 2 Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 3 Oncology, National Institute of Oncology, 1122 - Budapest/HU
  • 4 Oncology, Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza/IT
  • 5 Oncology, Seoul National University Bundang Hospital, Seongnam-si/KR
  • 6 Center For Lung Cancer, National Cancer Center, Goyang/KR
  • 7 Oncology, St Vincent Hospital The Catholic University of Korea, Suwon/KR
  • 8 Oncology, Montefiore Medical Center, New York/US
  • 9 Oncology, Innovative Clinical Research Institute, Whittier/US
  • 10 Oncology, Clearview Cancer Institute, Huntsville/US
  • 11 Oncology, Henry Ford Health System, Detroit/US
  • 12 Oncology, Lexington Oncology Associates, LLC, Lexington/US
  • 13 Oncology, Providence Saint Joseph Medical Center, Burbank/US
  • 14 Oncology, Dana-Farber Cancer Institute, Boston/US
  • 15 Research, Mirati Therapeutics, 92121 - San Diego/US
  • 16 Clinical Science, Mirati Therapeutics, 92121 - San Diego/US
  • 17 Pharmacology, Mirati Therapeutics, 92121 - San Diego/US
  • 18 Department Of Internal Medicine, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR


Abstract 1490


MGCD265 is a potent, orally available, small molecule RTK inhibitor of mutant and wild-type forms MET and of Axl, both of which mediate signals for cell growth, survival, and migration. Alterations in MET, including mutations and/or gene amplification, occur in approximately 7% of NSCLC and function as oncogenic drivers that promote cancer development and progression. Recently, various mutations located at or near the exon 14 splice site of MET (METex14del) have been identified and result in absence of expression of exon 14. Importantly, this non-expressed region encodes the Y1003 CBL ubiquitin ligase regulatory binding site that is required for CBL-dependent MET degradation and signal attenuation. Absence of this receptor domain results in sustained MET signaling, which has been implicated as an oncogenic driver in a subset of NSCLC. Furthermore, in xenograft models of NSCLC where METex14del and MET amplification are putative oncogenic drivers, MGCD265 induces robust tumor regression, and confirmed partial responses have been observed in patients with MET-altered NSCLC treated with MGCD265 in the Phase 1 setting.

Trial design

Pts with NSCLC characterized by activating genetic MET alterations identified in tumor tissue or circulating tumor DNA (ctDNA) and who have received at least one prior platinum-containing regimen for advanced disease are eligible for this global Phase 2 trial and are assigned to one of four cohorts based on the type of MET dysregulation and detection method: 1) mutations in tissue, 2) amplification in tissue, 3) mutations in ctDNA, and 4) amplification in ctDNA. The primary endpoint is Objective Response Rate (ORR) in accordance with RECIST 1.1. A Bayesian Predictive Probability Design is applied independently to each cohort of up to 45 patients, assuming p0 = 0.20 and p1 = 0.40. Secondary objectives include safety, tolerability, response duration, survival, correlation between tissue and ctDNA testing, and PK/PD. This study is currently open, and recruitment is ongoing.

Clinical trial identification

EudraCT: 2015-002070-21; Clinical trial registry number: NCT02544633

Legal entity responsible for the study

Mirati Therapeutics


Mirati Therapeutics


J. Christensen, R. Chao, D. Faltaos: Employee of Mirati Therapeutics; stocks ownership in Mirati Therapeutics. V. Tassell: Employee of Mirati Therapeutics and own stock. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings